NCT03970876View on ClinicalTrials.gov

Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 19, 2019

Primary Completion Date

September 11, 2019

Study Completion Date

December 23, 2019

Conditions
Moderate to Severe Glabellar Lines
Interventions
BIOLOGICAL

ATGC-100

Clostridium Botulinum Type A

BIOLOGICAL

Botox®

Clostridium Botulinum Type A

Trial Locations (1)

Unknown

Nowon Eulji Medical Center, Eulji University, Seoul

Sponsors
All Listed Sponsors
lead

EuBiologics Co.,Ltd

INDUSTRY

NCT03970876 - Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects | Biotech Hunter | Biotech Hunter